Compare AGM & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | NNNN |
|---|---|---|
| Founded | 1987 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2025 |
| Metric | AGM | NNNN |
|---|---|---|
| Price | $177.59 | $27.30 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $219.00 | N/A |
| AVG Volume (30 Days) | ★ 106.6K | 81.1K |
| Earning Date | 02-19-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 12.85 | N/A |
| EPS | ★ 17.55 | 0.06 |
| Revenue | ★ $377,946,000.00 | $6,920,153.00 |
| Revenue This Year | $14.80 | N/A |
| Revenue Next Year | $9.98 | N/A |
| P/E Ratio | ★ $10.40 | $424.57 |
| Revenue Growth | ★ 8.81 | N/A |
| 52 Week Low | $155.00 | $5.18 |
| 52 Week High | $212.24 | $55.65 |
| Indicator | AGM | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 55.56 | 49.59 |
| Support Level | $169.35 | $21.09 |
| Resistance Level | $174.48 | $34.00 |
| Average True Range (ATR) | 4.84 | 6.96 |
| MACD | 1.08 | 0.13 |
| Stochastic Oscillator | 62.74 | 33.15 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.